Clinical evaluation of (4S)-4-(3-[18F]Fluoropropyl)-L-glutamate (18F-FSPG) for PET/CT imaging in patients with newly diagnosed and recurrent prostate cancer.

(4S)-4-(3-[18F]Fluoropropyl)-L-glutamic acid (18F-FSPG) is a radiopharmaceutical for PET imaging of system xC- activity, which can be upregulated in prostate cancer. We present data on the first evaluation of newly diagnosed or recurrent prostate cancer patients with this radiopharmaceutical.